The U.S. Food and Drug Administration announced that Becton Dickinson and Company (NYSE:BDX) alerted customers to correct specific convenience kits by removing recalled sodium chloride ampules manufactured by Huons Co., Ltd., which Elevaris Medical Devices initially recalled.
Corrective Measures And Usage Guidelines
Convenience kits contain various surgical instruments, dressings, and pharmaceutical components designed for surgical procedures.
On August 10, BD sent a letter instructing healthcare providers to stop using the specific sodium chloride ampules found in the affected kits.
Facilities must quarantine their stock until they receive over-labels. Medical staff can safely use all other components within these surgical and procedural trays.
The company advises customers to label the impacted kits without covering essential regulatory details.
Once they open a tray in a sterile environment, staff must immediately remove and destroy the recalled ampule to preserve the sterility of the remaining items.
Potential Health Risks And Patient Monitoring
Patients could face exposure to endotoxins, microorganisms, or foreign particles.
These contaminants can induce severe reactions, including infections, micro-clots, systemic inflammatory responses, and organ failure. BD reported no deaths or serious injuries connected to this defect as of July 29.
Patients treated with the affected ampules require no specific follow-up if they remain asymptomatic.
Stock Performance and Technical Analysis
Becton Dickinson stock rose about 3% Wednesday as healthcare stocks led the market. The Nasdaq fell 0.22%, while the S&P 500 gained 0.22%. The move extends the stock’s recent rebound and suggests sector rotation continues to support BDX.
Becton Dickinson trades 7.7% above its 20-day simple moving average of $172.90 and 8.6% above its 200-day SMA of $171.42. It is also 16.5% above its 50-day SMA of $159.78 and 20% above its 100-day SMA of $155.12.
However, the relative strength index stands at 74.01. An RSI above 70 generally indicates overbought conditions and raises the risk of a near-term pause or pullback.
The longer-term technical picture remains mixed. The stock formed a death cross in March when its 50-day SMA fell below its 200-day SMA. BDX has since reclaimed both averages, but the bearish crossover has not yet reversed.
Resistance sits near $196, while support is around $153.50.
Becton Dickinson Analyst Outlook
The stock carries a Buy consensus rating with an average price forecast of $184.20.
RBC Capital maintained a Sector Perform rating and raised its price forecast to $190 on August 13. Citigroup maintained a Buy rating and raised its price forecast to $204 on August 7. RBC Capital had previously raised its price forecast to $180 on August 7.
Becton Dickinson Price Action
BDX Stock Price Activity: Becton Dickinson shares were up 3.02% at $186.23 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment